Md Abu Shufean
Overview
Explore the profile of Md Abu Shufean including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
184
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeng J, Cruz-Pico C, Saridogan T, Shufean M, Kahle M, Yang D, et al.
JCO Clin Cancer Inform
. 2022 Jan;
6:e2100109.
PMID: 34990212
Purpose: Despite advances in molecular therapeutics, few anticancer agents achieve durable responses. Rational combinations using two or more anticancer drugs have the potential to achieve a synergistic effect and overcome...
2.
Zeng J, Shufean M
Emerg Top Life Sci
. 2021 Dec;
5(6):757-764.
PMID: 34874054
The rapid growth and decreasing cost of Next-generation sequencing (NGS) technologies have made it possible to conduct routine large panel genomic sequencing in many disease settings, especially in the oncology...
3.
Araya A, Zeng J, Johnson A, Shufean M, Rodon J, Meric-Bernstam F, et al.
Int J Med Inform
. 2020 Sep;
143:104261.
PMID: 32889387
Purpose: Genomic analysis of individual patients is now affordable, and therapies targeting specific molecular aberrations are being tested in clinical trials. Genomically-informed therapy is relevant to many clinical domains, but...
4.
Zeng J, Johnson A, Shufean M, Kahle M, Yang D, Woodman S, et al.
JCO Clin Cancer Inform
. 2019 Sep;
3:1-12.
PMID: 31550176
Genomic testing has become a part of routine oncology care and plays critical roles in diagnosis, prognostic assessment, and treatment selection. Thus, in parallel, the variety of genomic testing providers...
5.
Zeng J, Shufean M, Khotskaya Y, Yang D, Kahle M, Johnson A, et al.
JCO Clin Cancer Inform
. 2019 Jul;
3:1-11.
PMID: 31265323
Purpose: Many targeted therapies are currently available only via clinical trials. Therefore, routine precision oncology using biomarker-based assignment to drug depends on matching patients to clinical trials. A comprehensive and...
6.
Johnson A, Khotskaya Y, Brusco L, Zeng J, Holla V, Bailey A, et al.
JCO Precis Oncol
. 2018 Oct;
2017.
PMID: 30320296
Purpose: Precision oncology is hindered by the lack of decision support for determining the functional and therapeutic significance of genomic alterations in tumors and relevant clinically available options. To bridge...
7.
Kurnit K, Dumbrava E, Litzenburger B, Khotskaya Y, Johnson A, Yap T, et al.
Clin Cancer Res
. 2018 Feb;
24(12):2719-2731.
PMID: 29420224
With the increasing availability of genomics, routine analysis of advanced cancers is now feasible. Treatment selection is frequently guided by the molecular characteristics of a patient's tumor, and an increasing...
8.
Kurnit K, Bailey A, Zeng J, Johnson A, Shufean M, Brusco L, et al.
Cancer Res
. 2017 Nov;
77(21):e123-e126.
PMID: 29092956
High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular profiling is increasingly being used to guide cancer patient care, especially in advanced and incurable...
9.
Holla V, Elamin Y, Bailey A, Johnson A, Litzenburger B, Khotskaya Y, et al.
Cold Spring Harb Mol Case Stud
. 2017 Jan;
3(1):a001115.
PMID: 28050598
The anaplastic lymphoma kinase () gene plays an important physiologic role in the development of the brain and can be oncogenically altered in several malignancies, including non-small-cell lung cancer (NSCLC)...